Ray Co., Ltd. (KOSDAQ:228670)
6,250.00
+740.00 (13.43%)
At close: Dec 5, 2025
Ray Co., Ltd. Revenue
Ray Co., Ltd. had revenue of 30.33B KRW in the quarter ending September 30, 2025, with 35.00% growth. This brings the company's revenue in the last twelve months to 97.57B, down -13.31% year-over-year. In the year 2024, Ray Co., Ltd. had annual revenue of 79.84B, down -45.27%.
Revenue (ttm)
97.57B
Revenue Growth
-13.31%
P/S Ratio
1.00
Revenue / Employee
548.12M
Employees
178
Market Cap
97.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 79.84B | -66.04B | -45.27% |
| Dec 31, 2023 | 145.88B | 16.88B | 13.09% |
| Dec 31, 2022 | 129.00B | 38.66B | 42.80% |
| Dec 31, 2021 | 90.34B | 35.13B | 63.64% |
| Dec 31, 2020 | 55.20B | -17.90B | -24.49% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |